Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Carolina Bonilla
  • Sarah J Lewis
  • Richard M Martin
  • Jenny L Donovan
  • Freddie C Hamdy
  • David E Neal
  • Rosalind Eeles
  • Doug Easton
  • Zsofia Kote-Jarai
  • Ali Amin Al Olama
  • Sara Benlloch
  • Kenneth Muir
  • Graham G Giles
  • Fredrik Wiklund
  • Henrik Gronberg
  • Christopher A Haiman
  • Johanna Schleutker
  • Ruth C Travis
  • Nora Pashayan
  • Kay-Tee Khaw
  • Janet L Stanford
  • William J Blot
  • Stephen Thibodeau
  • Christiane Maier
  • Adam S Kibel
  • Cezary Cybulski
  • Lisa Cannon-Albright
  • Hermann Brenner
  • Jong Park
  • Radka Kaneva
  • Jyotsna Batra
  • Manuel R Teixeira
  • Hardev Pandha
  • Mark Lathrop
  • George Davey Smith

BACKGROUND: Epidemiological studies have observed a positive association between an earlier age at sexual development and prostate cancer, but markers of sexual maturation in boys are imprecise and observational estimates are likely to suffer from a degree of uncontrolled confounding. To obtain causal estimates, we examined the role of pubertal development in prostate cancer using genetic polymorphisms associated with Tanner stage in adolescent boys in a Mendelian randomization (MR) approach.

METHODS: We derived a weighted genetic risk score for pubertal development, combining 13 SNPs associated with male Tanner stage. A higher score indicated a later puberty onset. We examined the association of this score with prostate cancer risk, stage and grade in the UK-based ProtecT case-control study (n = 2,927), and used the PRACTICAL consortium (n = 43,737) as a replication sample.

RESULTS: In ProtecT, the puberty genetic score was inversely associated with prostate cancer grade (odds ratio (OR) of high- vs. low-grade cancer, per tertile of the score: 0.76; 95 % CI, 0.64-0.89). In an instrumental variable estimation of the causal OR, later physical development in adolescence (equivalent to a difference of one Tanner stage between pubertal boys of the same age) was associated with a 77 % (95 % CI, 43-91 %) reduced odds of high Gleason prostate cancer. In PRACTICAL, the puberty genetic score was associated with prostate cancer stage (OR of advanced vs. localized cancer, per tertile: 0.95; 95 % CI, 0.91-1.00) and prostate cancer-specific mortality (hazard ratio amongst cases, per tertile: 0.94; 95 % CI, 0.90-0.98), but not with disease grade.

CONCLUSIONS: Older age at sexual maturation is causally linked to a reduced risk of later prostate cancer, especially aggressive disease.

OriginalsprogEngelsk
Artikelnummer66
TidsskriftBMC Medicine
Vol/bind14
Sider (fra-til)1-11
Antal sider11
ISSN1741-7015
DOI
StatusUdgivet - 4 apr. 2016

Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk


Ingen data tilgængelig

ID: 174180508